Read by QxMD icon Read

Prostate cancer imrt

Ibrahim Abu-Gheida, Chandana A Reddy, Rupesh Kotecha, Michael A Weller, Chirag Shah, Patrick A Kupelian, Omar Mian, Jay P Ciezki, Kevin L Stephans, Rahul D Tendulkar
PURPOSE/OBJECTIVES: Long term outcomes with hypofractionated radiotherapy for prostate cancer are limited. We report 10-year outcomes for patients treated with intensity modulated radiation therapy (IMRT) for localized prostate cancer with 70 Gy in 28 fractions at 2.5 Gy/fraction. METHODS AND MATERIALS: The study included 854 consecutive patients with localized prostate cancer treated with moderately hypofractionated IMRT and daily image guidance at a single institution between 1998 and 2012...
February 2, 2019: International Journal of Radiation Oncology, Biology, Physics
Eugenia Mylona, Oscar Acosta, Thibaut Lizee, Caroline Lafond, Gilles Crehange, Nicolas Magné, Sophie Chiavassa, Stéphane Supiot, Juan David Arango Ospina, Borris Campillo-Gimenez, Joel Castelli, Renaud de Crevoisier
BACKGROUND AND PURPOSE: To apply a voxel-based analysis to identify urethro-vesical symptom-related subregions (SRSs) associated with acute and late urinary toxicity in prostate cancer radiotherapy. MATERIALS AND METHODS: A total of 272 prostate cancer patients treated with IMRT/IGRT were prospectively analyzed. Each patient's CT was spatially normalized to a common coordinate system (CCS) via nonrigid registration. The obtained deformation fields were used to map the dose of each patient to the CCS...
February 1, 2019: International Journal of Radiation Oncology, Biology, Physics
Dan Nguyen, Troy Long, Xun Jia, Weiguo Lu, Xuejun Gu, Zohaib Iqbal, Steve Jiang
With the advancement of treatment modalities in radiation therapy for cancer patients, outcomes have improved, but at the cost of increased treatment plan complexity and planning time. The accurate prediction of dose distributions would alleviate this issue by guiding clinical plan optimization to save time and maintain high quality plans. We have modified a convolutional deep network model, U-net (originally designed for segmentation purposes), for predicting dose from patient image contours of the planning target volume (PTV) and organs at risk (OAR)...
January 31, 2019: Scientific Reports
Flora Goupy, Stéphane Supiot, David Pasquier, Igor Latorzeff, Ulrike Schick, Erik Monpetit, Geoffrey Martinage, Chloé Hervé, Bernadette Le Proust, Joel Castelli, Renaud de Crevoisier
OBJECTIVES: No study has reported clinical results of external-beam radiotherapy specifically for T3b prostate cancer. The possibility of escalating the dose to the involved seminal vesicles (ISV) while respecting the dose constraints in the organs at risk is thus so far not clearly demonstrated. The objective of the study was to analyze the dose distribution and the clinical outcome in a large series of patients who received IMRT for T3b prostate cancer. MATERIALS AND METHODS: This retrospective analysis included all patients who received IMRT and androgen deprivation therapy for T3b prostate cancer, between 2008 and 2017, in six French institutions, with available MRI images and dosimetric data...
2019: PloS One
Stephanie R Rice, Gloribel Olexa, Arif Hussain, Heather Mannuel, Michael J Naslund, Pradip Amin, Young Kwok
PURPOSE/OBJECTIVE(S): Management of localized high-risk prostate cancer remains challenging. At our institution we performed a prospective phase II study of 2 years of androgen deprivation therapy (ADT), pelvic radiation, Cesium (Cs)-131 brachytherapy boost, and adjuvant docetaxel in high risk, localized prostate cancer with a primary endpoint of 3-year disease-free survival. MATERIALS/METHODS: Acute/chronic hematologic, gastrointestinal (GI) and genitourinary (GU) toxicities were scored based on the CTCAE v3...
January 22, 2019: American Journal of Clinical Oncology
L Irazola, B Sánchez-Nieto, M T García-Hernández, J A Terrón, J Roselló, M Ortiz-Seidel, M J Béjar, R Linares, S Vélazquez, F Sánchez-Doblado
There is a growing interest in the combined use of Stereotactic Body Radiation Therapy (SBRT) with Flattening Filter Free (FFF) due to the high local control rates and reduced treatment times, compared to conventionally fractionated treatments. It has been suggested that they may also provide a better radiation protection to radiotherapy patients as a consequence of the expected decrease in peripheral doses. This work aims to determine this reduction in unattended out-of-field regions, where no CT information is available but an important percentage of second primary cancers occur...
January 11, 2019: Radiation Protection Dosimetry
Zhong Su, Zuofeng Li, Randal Henderson, Bradford S Hoppe, Romaine Charles Nichols, Curtis Bryant, William Mendenhall, Nancy Mendenhall
To evaluate the planning target volume (PTV) margins for prostate cancer patients treated with initial intensity-modulated radiation therapy (IMRT) to pelvic lymph nodes and a proton boost to the prostate using cone-beam computed tomography (CBCT) and radiographs as image guidance, 
 We analyzed data from prostate patients (n = 15) treated with initial pelvic IMRT and a proton boost to the prostate. CBCT and 2-dimensional (2D) radiographs were used for IMRT and proton pre-treatment alignments, respectively...
January 10, 2019: Physics in Medicine and Biology
Hamid Abdollahi, Bahram Moid, Isaac Shiri, Abolfazl Razzaghdoust, Afshin Saadipoor, Arash Mahdavi, Hassan Maleki Galandooz, Seied Rabi Mahdavi
OBJECTIVE: To develop different radiomic models based on the magnetic resonance imaging (MRI) radiomic features and machine learning methods to predict early intensity-modulated radiation therapy (IMRT) response, Gleason scores (GS) and prostate cancer (Pca) stages. METHODS: Thirty-three Pca patients were included. All patients underwent pre- and post-IMRT T2-weighted (T2 W) and apparent diffusing coefficient (ADC) MRI. IMRT response was calculated in terms of changes in the ADC value, and patients were divided as responders and non-responders...
January 3, 2019: La Radiologia Medica
Beatrice Detti, Muhammed Baki, Carlotta Becherini, Calogero Saieva, Daniele Scartoni, Irene Giacomelli, Laura Trombetta, Cristina Muntoni, Emanuela Olmetto, Giulio Francolini, Ana Turkaj, Juliana Topulli, Cinzia Ciabatti, Giulio Carta, Linda Poggesi, Camilla Delli Paoli, Francesca Terziani, Roberta Grassi, Lorenzo Livi
PURPOSE: Prostatectomy, radiotherapy and watchful waiting are the main therapeutic options available for local stage of prostate cancer (PCa). We report our experience on 394 patients affected by prostate cancer primarily treated with high-dose, image-guided, IMRT, focusing on gastrointestinal, genitourinary toxicities and biochemical control. METHODS: From July 2003 to August 2014, 394 patients were treated with radical high-dose radiotherapy (HDRT) for prostate cancer; the mean total radiation dose was 79 Gy in standard fractions...
January 3, 2019: La Radiologia Medica
Yasushi Nakai, Nobumichi Tanaka, Isao Asakawa, Satoshi Anai, Makito Miyake, Shunta Hori, Yosuke Morizawa, Yoshihiro Tatsumi, Masatoshi Hasegawa, Tomomi Fujii, Kiyohide Fujimoto
The purpose of this study was to evaluate quality of life (QOL) in prostate cancer patients treated with 125I brachytherapy (BT), 125I brachytherapy combined with 3D conformal radiation therapy (BT+3D-CRT), or intensity-modulated radiation therapy (IMRT). We evaluated disease-related QOL in patients who underwent BT, BT+3D-CRT, or IMRT, using the Expanded Prostate Cancer Index Composite questionnaire before treatment and at 3 and 24 months post-treatment. Multivariate analyses were conducted to determine factors associated with a minimum important difference (MID) in urinary, bowel, sexual, and hormone domain scores at 3 and 24 months post-treatment...
December 20, 2018: Journal of Radiation Research
Shinya Takemoto, Yuta Shibamoto, Chikao Sugie, Yoshihiko Manabe, Takeshi Yanagi, Hiromitsu Iwata, Taro Murai, Satoshi Ishikura
We evaluated long-term outcomes of three protocols of intensity-modulated radiation therapy (IMRT) for localized prostate cancer. Between 2005 and 2014, 348 patients were treated with 5-field IMRT. The first 74 patients were treated with a daily fraction of 2.0 Gy to 74 Gy (low-risk prostate cancer) or 78 Gy (intermediate- or high-risk prostate cancer); then 101 patients were treated with 2.1-Gy daily fractions to 73.5 or 77.7 Gy. More recently, 173 patients were treated with 2.2-Gy fractions to 72.6 or 74...
December 19, 2018: Journal of Radiation Research
David Dearnaley, Clare L Griffin, Rebecca Lewis, Philip Mayles, Helen Mayles, Olivia F Naismith, Victoria Harris, Christopher D Scrase, John Staffurth, Isabel Syndikus, Anjali Zarkar, Daniel R Ford, Yvonne L Rimmer, Gail Horan, Vincent Khoo, John Frew, Ramachandran Venkitaraman, Emma Hall
PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase 2 noncomparative multicenter trial, 124 patients with locally advanced, high-risk prostate cancer were randomized between prostate-only IMRT (PO) (74 Gy/37 fractions) and prostate and pelvic lymph node IMRT (P&P; 74 Gy/37 fractions to prostate, 60 Gy/37 fractions to pelvis)...
December 6, 2018: International Journal of Radiation Oncology, Biology, Physics
Matthew Hoffmann, Jacqueline Pacey, Josie Goodworth, Andrea Laszcyzk, Richard Ford, Brendon Chick, Stuart Greenham, Justin Westhuyzen
Aim: To assess a class solution template for volumetric-modulated arc therapy (VMAT) for prostate cancer using plan analysis software. Background: VMAT is a development of intensity-modulated radiotherapy (IMRT) with potential advantages for the delivery of radiotherapy (RT) in prostate cancer. Class solutions are increasingly used for facilitating RT planning. Plan analysis software provides an objective tool for evaluating class solutions. Materials and methods: The class solution for VMAT was based on the current static field IMRT template...
January 2019: Reports of Practical Oncology and Radiotherapy
Dirk Bottke, Detlef Bartkowiak, Alessandra Siegmann, Reinhard Thamm, Dirk Böhmer, Volker Budach, Thomas Wiegel
BACKGROUND: For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) offers a second chance of cure. European guidelines (EAU) recommend SRT at a PSA < 0.5 ng/ml. We analyze the efficacy of SRT given according to this recommendation and investigate the predictive power of the post-SRT PSA nadir. METHODS: Between 1998 and 2013, 301 patients of two university hospitals received SRT at a PSA < 0.5 ng/ml (median 0...
November 28, 2018: Prostate Cancer and Prostatic Diseases
B A Jereczek-Fossa, A Maucieri, G Marvaso, S Gandini, C Fodor, D Zerini, G Riva, O Alessandro, A Surgo, S Volpe, G Fanetti, S Arculeo, M A Zerella, S Parisi, P Maisonneuve, A Vavassori, F Cattani, R Cambria, C Garibaldi, A Starzyńska, G Musi, O De Cobelli, M Ferro, F Nolè, D Ciardo, R Orecchia
To report toxicity and efficacy outcome of moderately hypofractionated image-guided external-beam radiotherapy in a large series of patients treated for prostate cancer (PCa). Between 10/2006 and 12/2015, 572 T1-T3N0M0 PCa patients received 70.2 Gy in 26 fractions at 2.7 Gy/fraction: 344 patients (60%) with three-dimensional conformal radiotherapy (3D-CRT) and 228 (40%) with intensity-modulated radiotherapy (IMRT). Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and Houston definition (nadir + 2) were used for toxicity and biochemical failure evaluation, respectively...
November 27, 2018: Medical Oncology
Ben G L Vanneste, Florian Buettner, Michael Pinkawa, Philippe Lambin, Aswin L Hoffmann
Background and purpose: To evaluate spatial differences in dose distributions of the ano-rectal wall (ARW) using dose-surface maps (DSMs) between prostate cancer patients receiving intensity-modulated radiation therapy with and without implantable rectum spacer (IMRT+IRS; IMRT-IRS, respectively), and to correlate this with late gastro-intestinal (GI) toxicities using validated spatial and non-spatial normal-tissue complication probability (NTCP) models. Materials and methods: For 26 patients DSMs of the ARW were generated...
January 2019: Clinical and Translational Radiation Oncology
Jonathan Hayman, Knut H Hole, Therese Seierstad, Jamie Perin, Theodore L DeWeese, Phuoc T Tran, Wolfgang Lilleby
BACKGROUND: The recurrence patterns of high-risk, N1 prostate cancer after radiation therapy (RT) including the pelvic lymph nodes have not been fully investigated. MATERIAL AND METHODS: We have a prospective clinical study since 2004 that has followed 138 men with locally advanced prostate cancer (T1-T4N0-N1M0) treated with definitive RT encompassing the prostate and pelvic lymph nodes and long-term androgen deprivation therapy (ADT). Forty nine of the 52 patients that developed recurrence were imaged at biochemical failure to detect the site of recurrence...
November 13, 2018: Urologic Oncology
Arne Grün, Michael Kawgan-Kagan, David Kaul, Harun Badakhshi, Carmen Stromberger, Volker Budach, Dirk Böhmer
BACKGROUND AND PURPOSE: To evaluate the effect of changes in bladder volume during high-dose intensity-modulated-radiotherapy (IMRT) of prostate cancer on acute genitourinary (GU) toxicity and prospectively evaluate a simple biofeedback technique for reproducible bladder filling with the aim of reducing acute GU toxicity. METHODS: One hundred ninety-three patients were trained via a biofeedback mechanism to maintain a partially filled bladder with a reproducible volume of 200-300 cc at planning CT and subsequently at each fraction of radiotherapy...
November 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Yasushi Nakai, Nobumichi Tanaka, Satoshi Anai, Makito Miyake, Isao Asakawa, Yosuke Morizawa, Shunta Hori, Kazumasa Torimoto, Tomomi Fujii, Masatoshi Hasegawa, Kiyohide Fujimoto
Purpose: The aim of this study was to evaluate the chronological changes in lower urinary tract symptoms (LUTSs), disease-related quality of life (QOL), and health-related QOL (HR-QOL) of patients who received intensity-modulated radiotherapy (IMRT). Patients and methods: In 121 patients who had received IMRT and were followed up for >2 years, the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), Expanded Prostate Cancer Index Composite (EPIC), and 8-Item Short-Form Health Survey (SF-8) were used before IMRT, at the halfway point in IMRT, immediately after IMRT, and 1-24 months after the completion of IMRT...
2018: Research and Reports in Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"